Stevenage Bioscience Catalyst announces Oliver King as new Development and Leasing Director

Stevenage Bioscience Catalyst (SBC), a leading location for development and commercialisation of cutting-edge therapeutics, is pleased to announce that Oliver (Oli) King joined as Development and Leasing Director on 6th December 2022.

Dr Sally Ann Forsyth OBE, CEO at SBC said “With his extensive experience in the property industry and enthusiasm for the science park sector, Oliver is ideally placed to support the growing cluster of exciting companies here at SBC. We are delighted to welcome him to the team and look forward to working with him in the future”.

Oliver King commented “I’m delighted to be a member of the SBC family and am incredibly excited to be working alongside Europe’s largest cluster of entities specialising in the evolution of Cell and Gene Therapy. The Real Estate Life Science sector continues to grow at an unprecedented rate, and I feel very privileged to now be a part of it. I look forward to working with Sally Ann and the team amongst all the amazing scientists housed at SBC.“